Etalocib sodium
Based on 2 publication(s) in Google Scholar
Etalocib (LY293111) sodium, an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib sodium prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib sodium induces apoptosis.
For research use only. We do not sell to patients.
- CAS No.: 152608-41-8
- Formula: C33H32FNaO6
- Molecular Weight:566.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Etalocib sodium
MoreAll Leukotriene Receptor Isoforms
More
Biological Activity
|
LTB4 |
Etalocib sodium elicits a concentration-dependent inhibition of LTB4 induced CD11b up-regulation[1].
Etalocib sodium is an extremely potent and selective antagonist of human neutrophil function in vitro[2].
Etalocib (250 and 500 nM, 24-72 h) sodium induces apoptosis and inhibits proliferation in human pancreatic cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Etalocib (10 mg/kg) sodium inhibits A23187-induced lung inflammatory changes at 1 h[2].
Etalocib (250 mg/kg/day, orally) sodium inhibits growth of human pancreatic cancer xenografts in athymic mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 152608-41-8
-
Molecular Weight 566.59
-
Formula C33H32FNaO6
-
SMILES
O=C(C1=C(OC2=CC=CC(OCCCOC3=C(CC)C=C(C4=CC=C(F)C=C4)C(O)=C3)=C2CCC)C=CC=C1)O[Na]
-
Synonyms
LY293111 sodium; VML 295 sodium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cancer Sci
CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway. [Abstract]2025 Apr;116(4):1115-1125. PMID: 39905783 -
Antiviral Res
Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses. [Abstract]2024 Nov:231:106012. PMID: 39332537
Purity & Documentation
References
[1]. P Marder, et al. Blockade of Human Neutrophil Activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- Hydroxyphenoxy]propoxy]phenoxy]benzoic Acid (LY293111), a Novel Leukotriene B4 Receptor Antagonist. Biochem Pharmacol. 1995 May 26;49(11):1683-90. [Content Brief]
[2]. S A Silbaugh, et al. Pharmacologic Actions of the Second Generation Leukotriene B4 Receptor Antagonist LY29311: In Vivo Pulmonary Studies. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):397-404. [Content Brief]
[3]. Wei-Gang Tong, et al. Leukotriene B4 Receptor Antagonist LY293111 Inhibits Proliferation and Induces Apoptosis in Human Pancreatic Cancer Cells. Clin Cancer Res. 2002 Oct;8(10):3232-42. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Etalocib sodium Related Classifications
HY-13628A Related Classifications
Powered by Bioz